Sustainability & Climate

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

Amidst record vacancies, a Portland university makes a debt-free move, betting on integrative medicine to revitalize both patients and the city center.

With promising clinical data and a streamlined FDA path, a smarter molecule could finally offer a better, more tolerable treatment for idiopathic pulmonary fibrosis.

Sensorion clears a key safety hurdle for its infant hearing loss gene therapy, but early data reveals a tight race to market against formidable rivals.

A junior miner's auditor and finance chief changes signal a calculated move to de-risk its path to becoming a major developer of a 'green' gold mine.

Designer Hiromi Asai redefines Japanese heritage at Miami Art Week, transforming sacred kimono textiles into sculptural menswear and making a bold market play.

Swedish innovator SciBase is overhauling its capital structure with a complex warrant buyback. Is this a strategic masterstroke or a necessary defensive play?

Healthcare tech firm StaffDNA’s title sponsorship of the Cure Bowl is more than a game—it's a calculated move blending branding with a cancer research mission.

Massey Ferguson's award to the World's Oldest Rodeo is more than a gift; it's a strategic look at how heritage brands are powering community impact.

BlackRock has once again boosted its holding in Finnish drugmaker Orion to over 5%. We decode what this calculated move signals for Orion's future.

New 48-month data for Xenon's azetukalner shows remarkable efficacy, but its real strategy to tackle the total burden of epilepsy may be the bigger story.

New long-term data suggests zorevunersen may modify Dravet syndrome, not just treat it. A look at the science, the strategy, and the stakes.

A landmark government scheme is injecting billions into innovation. Can venture capitalists like Beyond Ventures turn this capital into a tech and health boom?

New data on RAP-219 reveals more than just seizure control; it shows a strategic play to redefine treatment and capture the neurology market.

Whisker's Litter-Robot is now HSA/FSA eligible, a strategic move redefining medical expenses and giving it a major edge in the booming pet tech market.

Lexicon's sotagliflozin may revolutionize HFpEF treatment by targeting adipose tissue, a move that could differentiate it in a crowded market.

Canadian startup Tracktile secures funding to democratize AI, offering small food manufacturers the predictive operational tools once reserved for giants.

Intensity Therapeutics has a promising cancer therapy in late-stage trials, but can its scientific innovation outpace a looming Nasdaq delisting threat?

Getlink's latest figures show a slowdown in cross-Channel traffic, revealing deep strains in the automotive sector and growing consumer caution.

Henri Beaufour’s passing transfers a major Ipsen stake to a charity. We analyze the governance safeguards and what it means when philanthropy enters the boardroom.